Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1/2 2Phase 1 1

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Plasma cell 1Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 121Breast Neoplasms 81Neoplasms 75Colorectal Neoplasms 65Neoplasm Metastasis 64Leukemia, Myeloid, Acute 62Prostatic Neoplasms 59Recurrence 53Pancreatic Neoplasms 51Ovarian Neoplasms 50Multiple Myeloma 50Triple Negative Breast Neoplasms 36Lung Neoplasms 36Melanoma 35Squamous Cell Carcinoma of Head and Neck 33Lymphoma, Non-Hodgkin 33Glioblastoma 31Carcinoma, Renal Cell 29Precursor Cell Lymphoblastic Leukemia-Lymphoma 28Lymphoma, Large B-Cell, Diffuse 28Lymphoma 28Endometrial Neoplasms 28Carcinoma, Hepatocellular 28Stomach Neoplasms 26Small Cell Lung Carcinoma 26Leukemia, Lymphocytic, Chronic, B-Cell 26Myelodysplastic Syndromes 24Lymphoma, Follicular 24Lymphoma, B-Cell 24Sarcoma 23

Interventions

selinexor 1pazopanib 1Proton Therapy 1Ifosfamide 1Doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Hemangiosarcoma × 90 days × Clear all
NCT06239272 2026-05-19

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

St. Jude Children's Research Hospital

Phase 1/2 Recruiting
139 enrolled
Plasma cellSarcoma

Histiocytoma, Angiomatoid Fibrous, Chondrosarcoma, Extraskeletal Myxoid, Fibrosarcoma, Glomus Tumor, Granuloma, Plasma Cell, Hemangiosarcoma, Liposarcoma, Myoepithelioma, Sarcoma, Osteosarcoma, Disorders of Sex Development, Granular Cell Tumor, Neoplasms, Adipose Tissue, Liposarcoma, Myxoid, Dermatofibrosarcoma, Sarcoma, Clear Cell, Smooth Muscle Tumor, Nerve Sheath Neoplasms, Neurofibrosarcoma, Hemangioendothelioma, Epithelioid, Vascular Neoplasms, Solitary Fibrous Tumors

NCT05826600 2026-04-24

A Study of OMX-0407 in Patients With Previously Treated Solid Tumours That Can't be Removed Surgically

iOmx Therapeutics AG

Phase 1/2 Terminated
68 enrolled
GenitourinarySarcoma

Carcinoma, Renal Cell, Hemangiosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡